Abbott Laboratories (N:ABT)
Business Focus: Medical Equipment, Supplies & Distribution
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 100 Abbott Park Road, Abbot Park ABBOTT PARK IL 60064-3500 |
| Tel: | N/A |
| Website: | https://www.abbott.com |
| IR: | See website |
| Key People | ||
| Robert B. Ford Chairman of the Board, Chief Executive Officer | Randel W. Woodgrift Senior Vice President - Cardio Rhythm Management | Philip P. Boudreau Chief Financial Officer, Senior Vice President - Finance |
| Robert E. Funck Executive Vice President - Finance | Hubert L. Allen Executive Vice President, General Counsel, Secretary | Mary K. Moreland Executive Vice President - Human Resources |
| Lisa D. Earnhardt Executive Vice President, Group President - Medical Devices | Louis H. Morrone Executive Vice President - Core Diagnostics | Daniel Gesua Sive Salvadori Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products | Andrea Wainer Executive Vice President - Rapid and Molecular Diagnostics |
| Business Overview |
| Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Abbott Laboratories revenues decreased 8% to $40.11B. Net income decreased 17% to $5.72B. Revenues reflect Diagnostics Products segment decrease of 40% to $9.99B, United States segment decrease of 15% to $15.45B, All other Countries segment decrease of 5% to $14.08B, Japan segment decrease of 22% to $1.51B. Net income also reflects Diagnostics Products segment income decrease of 64% to $2.43B. |
| Employees: | 114,000 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $196,900M as of Dec 31, 2023 |
| Annual revenue (TTM): | $40,109M as of Dec 31, 2023 |
| EBITDA (TTM): | $9,965M as of Dec 31, 2023 |
| Net annual income (TTM): | $5,723M as of Dec 31, 2023 |
| Free cash flow (TTM): | $1,503M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $7,400M as of Dec 31, 2023 |
| Shares outstanding: | 1,735,184,289 as of Jan 31, 2024 |
| Index Membership: | S&P 500 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.